Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

NCT03074513 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

133

Enrollment

OTHER

Sponsor class

Conditions

Appendix Adenocarcinoma
Human Papillomavirus-Related Anal Squamous Cell Carcinoma
Human Papillomavirus-Related Cervical Squamous Cell Carcinoma
Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis
Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma
Neuroendocrine Carcinoma
Pancreatic Neuroendocrine Tumor
Recurrent Merkel Cell Carcinoma
Recurrent Nasopharynx Carcinoma
Recurrent Peritoneal Malignant Mesothelioma
Recurrent Pleural Malignant Mesothelioma
Stage III Merkel Cell Carcinoma AJCC v7
Stage III Nasopharyngeal Carcinoma AJCC v7
Stage III Pleural Malignant Mesothelioma AJCC v7
Stage IV Merkel Cell Carcinoma AJCC v7
Stage IV Nasopharyngeal Carcinoma AJCC v7
Stage IV Pleural Malignant Mesothelioma AJCC v7
Stage IVA Nasopharyngeal Carcinoma AJCC v7
Stage IVB Nasopharyngeal Carcinoma AJCC v7
Stage IVC Nasopharyngeal Carcinoma AJCC v7
Vaginal Squamous Cell Carcinoma, Not Otherwise Specified

Interventions

DRUG: Atezolizumab
BIOLOGICAL: Bevacizumab
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]